Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades.  Sana is building differentiated capabilities across the spectrum of cell and gene therapy. 
 
Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body.  We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders.
 
Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.

Sana Biotechnology, Inc.

Over 8 million people worldwide are currently living with type 1 diabetes. At Sana, we’re advancing our hypoimmune platform for the potential treatment of this and other serious diseases. 

Check out The Economist article below highlighting promising preclinical diabetes data using our hypoimmune technology that were recently published in Cell Stem Cell.

https://lnkd.in/gRcYJtY9

Cancer prevention awareness is a key step towards a healthier future. Together, let's inspire change, promote healthy lifestyles, and drive advancements in cancer innovation to prevent and treat cancer. 

Learn more about cancer prevention here: https://lnkd.in/gT2vd6hZ

#CancerPrevention #BiotechInnovation #Cellengineering #CellTherapy

We are excited to share the publication of preclinical diabetes data in Cell Stem Cell. 
 
Published data demonstrate that transplantation of Sana’s engineered allogeneic, hypoimmune (HIP)-modified pancreatic islet cells provided lasting glucose control, enabling the achievement of exogenous insulin independence without immunosuppression in a diabetic non-human primate (NHP). 
 
These data underscore the diverse and vast potential of the hypoimmune platform to transform the diabetes treatment landscape and beyond. 
 
Read more here: https://lnkd.in/g589pFsJ

Today we announced the closing of an upsized $189M public offering. 
 
We would like to recognize the tremendous support from healthcare investors, as well as the significant interest from scientific and healthcare communities, as we collectively work to change the possible for patients. 

Read more here: https://lnkd.in/gmX_ZVnV

At Sana, we recognize first-hand the vital role women play in driving innovation and shaping the future of science and medicine. 

We are committed to continuing to break barriers, inspire the next generation, and build a more inclusive and diverse scientific community. 

#WomenInScience #GirlsInScience #BiotechInnovation #STEMdiversity

Sana welcomes the Year of the Wood Dragon, a revered symbol in Chinese culture embodying growth, prosperity, and good fortune. 

We Look forward to a year filled with creativity, innovation, and abundant opportunities. #LunarNewYear

At Sana, our focus on changing the possible for patients through engineered cells is matched by our commitment to bring awareness to cancer prevention and early detection. 

Join us in fostering awareness, driving innovation, and uniting against cancer. Together, we can make strides in both treatment and prevention. 
 
#WorldCancerDay #CellTherapy #CancerPrevention #EarlyDetection

Sana will be honoring Black History Month throughout the month of February through various events within our community. 

The Sana Pledge is a commitment to ending inequality for all, and a meaningful part of our effort is directed toward countering racism and supporting the Black community.

"The future never just happened. It was created." -- Mae Jemison

#BlackHistoryMonth

We are honored for another feature in BioSpace’s annual Hotbed Maps, representing the most thriving life science regions across the country. With three primary office locations, Sana will be featured in the #BioForest, #BiotechBay, and #Genetown maps. 

In each of our locations, employees are relentless in discovering therapies that shift the possible for patients. 

Learn more about Sana, our culture, and open positions here: https://sana.com/join-us/

#hiring #jobsatSana

Today we memorialize the millions of lives lost and honor those who survived the acts of the Holocaust. We must stand united against hatred and intolerance, ensuring such atrocities never happen again.
 
#HolocaustRemembranceDay

Domain Not Resolving

HSTS

Google Maps

Content Delivery Network

Amazon

Font Awesome

Mobile Non Scaleable Content

jsDelivr

BootstrapCDN

Microsoft

Executive Vice President, Chief Business Officer

Christian Hordo

Chief Technology Officer

Edward Rebar

Co-Founder

Jacob Rubens

Chief Financial Officer

Nate Hardy

Senior Director: Viral Vector Discovery and Head of in Vivo Research for T-Cell Therapies

Neal Van Hoeven

Chief People Officer

Robin Andrulevich

Executive Vice President and Global Head of Research and Development

Sunil Agarwal

Manager, Bioanalytical CRO Management

Tauqeer Zaidi

Owner

Vance Klein

Vice President - Immunology

Aaron E. Foster

Michelle Seitz

Michael Mee

Richard C. Mulligan

Head of SanaX

SVP and Chief Technical Officer

Aaron Foster

Farah Anwar

Head of R&D Operations and IDE Leader

Shanna Peek

SVP, Corporate Operations

Washington Companies With More Than 50 Employees

Health Care Companies With Fewer Than 1000 Employees (Top 10K)

Washington Companies With Fewer Than 1000 Employees (Top 10K)

Greater Seattle Area Companies With More Than 10 Employees (Top 10K)

Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients.

Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases.

The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.

Post-IPO Equity - Sana Biotechnology

Series A - Sana Biotechnology

Seed Round - Sana Biotechnology

Seattle

Washington

United States

North America

Sana Biotechnology

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA

Opportunity Arises for Co. With Cell Pouch Research Report

Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

Sana Biotechnology Non-GAAP EPS of -$0.27

Sana strips back cancer, CNS programs as cell therapy biotech warns of further layoffs

Sana cuts programs, staff, as it refocuses on autoimmune assets

Sana Biotechnology just downgraded at JMP Securities, here's why

Sana narrows focus again to zero in on diabetes and autoimmune disease

This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

A treatment designed to avoid immune rejection and target cancer cells, using modified T cells from healthy donors.

A platform aiming to modify genes within the body to treat diseases, focusing on delivery, gene modification, and execution.

Cells are collected and modified outside the body to treat diseases, including autologous and allogeneic cell therapies.

A hypoimmune allogeneic CD19-directed CAR T cell therapy in Phase 1 study for B-cell malignancies.

A hypoimmune allogeneic CD19-directed CAR T cell therapy in Phase 1 study for severe B-cell mediated autoimmune diseases.

A hypoimmune allogeneic CD22-directed CAR T cell therapy in Phase 1 study for B-cell malignancies.

Finland

Europe

India

Asia

Estonia

South Africa

Africa

HTML5

F5 NGINX

Microsoft Outlook

jQuery

Google Tag Manager

Google Analytics

Wordpress

Vimeo

Google Fonts

GoDaddy Premium DNS

Caribou is a biotechnology company that focuses on CRISPR-based gene editing technologies.

Caribou

Editas Medicine is a biotechnology company specializing in developing gene editing therapies.

Editas Medicine

eGenesis is a biotechnology company focused on xenotransplantation and gene editing technologies.

eGenesis

Sana Biotechnology, Inc. focuses on utilizing engineered cells as medicines and develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, and B-cell-mediated autoimmune conditions.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

news impact assignment basic	general	Mar 8, 2024 1:14 AM	c4e9ade8
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 1:14 AM	59905644
company summary	general
signals	general	Mar 8, 2024 1:14 AM	569b15e9
crunchbase trigger	general	Nov 22, 2024 7:44 AM	ae279717
crunchbase profile	general	Nov 22, 2024 8:45 AM	66b13032
li profile	general	Mar 8, 2024 1:14 AM	4692b2dc
translate crunchbase fundingrounds	general	Nov 22, 2024 10:59 AM	b00762d3
peers	general	Mar 8, 2024 1:14 AM	643903b1
news basic	general	Mar 8, 2024 1:14 AM	7560899e
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:SANA

Sana Biotechnology, Inc.

Last Close

2.35

22/11 21:00

Market Cap

1.15B

Beta: -

Volume Today

1.82M

Avg: -